Combining CDKN2A/B hemizygous-loss and focal gene amplifications reveals a group of IDHmut-astrocytoma patients with an intermediate prognosis, refining IDHmut-astrocytoma classification. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).